Publication Name	World Journal of Hepatology
Manuscript ID	4210
Country	Greece

Received	2013-06-20 09:37
Peer-Review Started	2013-06-20 14:27
To Make the First Decision
Return for Revision
Revised
Second Decision	2013-06-20 10:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-06-21 22:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-21 13:33
Publish the Manuscript Online	2013-07-25 09:10

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat
Manuscript Source	Invited Manuscript
All Author List	Kalliopi Zachou, Alexandros Sarantopoulos, Nikolaos K Gatselis, Themistoklis Vassiliadis, Stella Gabeta, Aggelos Stefos, Asterios Saitis, Panagiota Boura and George N Dalekos
Funding Agency and Grant Number
Corresponding Author	George N Dalekos, MD, PhD, Professor, Head, Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Biopolis, 41110 Larissa, Greece. dalekos@med.uth.gr
Key Words	Immunosuppression; Hepatitis B; Anti-hepatitis B virus core antibody positivity; Occult hepatitis B virus infection; Rituximab
Core Tip	Patients with occult or resolved hepatitis B undergoing chemotherapy or immunosuppression are potentially at risk of hepatitis B virus (HBV) reactivation which can be disastrous since it can lead to acute liver failure and death. In this report, we describe the characteristics and outcome in one of the larger series of patients (n = 14) with occult or resolved HBV who experienced HBV reactivation after receiving immunosuppression though they were initially HBV surface antigen-negative. Most of patients had received rituximab. We showed that these patients can develop severe HBV reactivation even 2 years after stopping immunosuppression, whereas prompt antiviral treatment on diagnosis of reactivation can be lifesaving.
Publish Date	2013-07-25 09:10
Citation	Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol 2013; 5(7): 387-392
URL	http://www.wjgnet.com/1948-5182/full/v5/i7/387.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i7.387

Full Article (PDF)	WJH-5-387.pdf
Manuscript File	2807-Review.doc
Answering Reviewers	2807-Answering reviewers.doc
Copyright License Agreement	2807-Copyright assignment.pdf
Peer-review Report	2807-Peer review(s).pdf
Scientific Editor Work List	2807-Scientific editor work list.doc